ARS Pharmaceuticals, Inc. Financials

Market Capitalization None as of None

Valuations Metrics as of May. 5, 2024

Trailing PE
Forward PE	-18.09
Price to Sales TTM	$30973.91
Price to Book MRQ	$4.01
Enterprise to Revenue	22827.29
Enterprise to EBITDA	-10.15

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	0.00%
Operating Margin	-225066.67%
Return on Assets TTM	-16.40%
Return on Equity TTM	-21.59%

Income Statement

Revenue TTM	$30,000
Revenue per Share TTM	$0.00
Quarterly Revenue Growth	%
Gross Profit TTM	$0
EBITDA	$-67,447,000
Net Income to Common TTM	$-54,365,000
Diluted EPS TTM	$-0.57
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	$228,360,000
Total Cash per Share MRQ	$2.37
Total Debt MRQ	$
Total Debt to Equity MRQ	0.12
Current Ratio MRQ	96.92
Book Value per Share MRQ	$2.39

Cash Flow

Operating Cash Flow TTM	$-59,266,000
Levered Free Cash Flow TTM	$-36,174,000

SPRY Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	96,894,400
Float Shares	37,137,658
Avg 10 Volume	469,075
Avg 30 Volume	None
Shares Short	6,087,282
Short Ratio	6.57
Short % of Shares	11.92%
% Held by Insiders	27.67%
% Held by Institutions	65.24%

Stock Price Summary

Beta
Fifty Two Week Low	$2.55
Fifty Two Week High	$11.27
Fifty Two Week Change	38.36%
Day 50 MA	$8.94
Day 200 MA	$6.44

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date